You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TEC-Ari? Using MSCs to Engineer Articular Cartilage
SBC: ARISTON MEDICAL , INC. Topic: N/ADESCRIPTION (provided by applicant): The work performed in this proposal will help in the development of tissue engineered cartilage constructs, to be commercialized as the TEC-AriTM method. The product is intended to be a tissue engineering service avail able to health care providers that involves the use of autologus cells to construct in vitro articular cartilage. The neotissue, produced using ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Treatment and/or Prevention of Urinary Tract Infections
SBC: Biomedical Development Corporation Topic: N/ADESCRIPTION (provided by applicant): Urinary tract infections (UTIs) are very common bacterial infections that affect millions of people each year. In the U.S., approximately 10% of women are diagnosed with cystitis annually, with an associated cost of 1. 6 billion. UTIs are also the most commonly occurring nosocomial infection, and nosocomial UTIs mostly arise as a consequence of indwelling urin ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
A Bioactive Prosthetic Vascular Graft
SBC: BIOSURFACES INC Topic: N/ADESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are comprised of either polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Medium (6-8mm) and small (l t5mm) internal diameter (I.D.) prosthetic arterial grafts continue to have unacceptably high failure rates when used in the clinical setting. T ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
In vivo Selection of Ribosomal Aptamers for Improved Bioremediation
SBC: Biotex, Inc. Topic: N/ADESCRIPTION (provided by applicant): Bioremediation technologies use microorganisms to reduce, eliminate, contain, or transform to benign products contaminants present in soils, sediments, water, and air. While biological treatment of domestic and industri al waste has been employed for some time, only recently have genetic engineering approaches been applied to augment microbial capabilities. Mos ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
ASSAY FOR MUTATIONS IN STEM CELLS AND THEIR DERIVATIVES
SBC: INCELL CORPORATION, LLC Topic: N/ADESCRIPTION (provided by applicant): Stem cell-based therapies hold great promise for the treatment of numerous debilitating diseases and conditions. However, the success of this approach is dependent upon maintenance of genetic integrity in these cells, b oth before and after induction of differentiation to yield specific, functional cell types in vitro, and/or transplantation of differentiated d ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health